Business Wire

New collaboration combines Mekonos’ novel ex vivo delivery platform with bit.bio’s unique opti-ox™ precision cellular reprogramming technology to accelerate the development of human cells for research, drug discovery and next-generation cell therapiesSAN FRANCISCO--(BUSINESS WIRE)--Mekonos, Inc., a biotech platform company...

Attention improved in more than 80 percent of adults with ADHD, and over one-third of participants no longer exhibited an attention deficit following treatment Improvements in attention were nearly seven times larger than those seen in the pivotal trial that...

Solid first quarter; consistent with full year 2023 objectives Adjusted revenue of €1,407 million, Adjusted recurring EBIT margin of 7.6% 10% year-over-year growth in Adjusted net profit of €80 million Preparing future core with the creation of Rely – a new integrated...

LONDON--(BUSINESS WIRE)--#ai--MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, has closed a £5 million (US$6.2 million) seed funding extension round to build its precision therapeutics discovery platform for metabolic syndrome-related medical conditions. The round was led by London-based...

PARIS--(BUSINESS WIRE)--Regulatory News: Technip Energies (PARIS: TE) and John Cockerill, two industrial leaders in the hydrogen market, announce the launch of Rely, a unique provider of integrated and competitive green hydrogen solutions. Energy and heavy industries are at a major turning...

SAN JOSE, Calif.--(BUSINESS WIRE)--OneLight Sensing, LLC announced today the appointment of Rear Admiral (Ret) Christian “Boris” Becker as President of OneLight Sensing, LLC. Becker completed his 30-plus year career in the U.S. Navy as the senior space acquisition officer...

Performance raised: Strong financial results in 2022 and a resilient Q1 2023 EV ramp up intensified: All-electric portfolio includes 7 cars and 4 vans from Mercedes-Benz, sales of electric cars more than doubled in 2022 Operating System presented: Precursor of new...

Oral presentation on SAR’579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; SAR’579 / IPH6101 is ANKET® platform lead asset and under development by partner Sanofi Two Trial in Progress posters including monalizumab in non-small cell lung...

READING, Pa.--(BUSINESS WIRE)--Cambridge-Lee Holdings, Inc, has announced its audited consolidated results for the fiscal year 2022. CAMBRIDGE-LEE HOLDINGS, INC. AND SUBSIDIARIES (A Wholly Owned Subsidiary of Tubo de Pasteje S.A. de C.V.)   CONSOLIDATED BALANCE SHEETS As of December 31, 2022 and December 31,...

MEXICO CITY--(BUSINESS WIRE)--Industrias Unidas, S.A. de C.V. (“IUSA” or the “Company”) has announced its audited results for the twelve months ended December 31 of 2022. Figures are audited and have been prepared in accordance with Mexican Financial Reporting Standards...